Introduction:
Immunogenicity Risk Assessment of Peptide Impurities is a key part of pharmaceutical development whenever an unexpected impurity appears in a generic peptide drug. Therapeutic peptides offer high target specificity, but sequence changes, chemical modifications, aggregation, or product-related impurities can alter their biological properties and potentially influence immune recognition.
For teams preparing an Abbreviated New Drug Application (ANDA), a new impurity raises several questions:
- What is the impurity, and how did it form?
- How does it differ structurally from the active pharmaceutical ingredient (API) and the RLD?
- How much exposure could a patient have?
- What evidence shows it does not create a meaningful immunogenicity concern?
Answering these takes more than a routine purity test. It requires analytical chemistry, manufacturing knowledge, exposure assessment, and a scientifically justified risk evaluation. For broader context, see our overview of therapeutic peptide characterization for NDA and ANDA programs.
Summary:
- Immunogenicity Risk Assessment of Peptide Impurities is a structured evaluation of whether a newly identified impurity in a generic peptide could trigger an unwanted immune response.
- Peptide impurities arise from incomplete synthesis, side reactions, oxidation, deamidation, aggregation, purification limits, or storage degradation.
- A defensible assessment combines impurity identification, structural characterization, comparison with the reference listed drug (RLD), exposure estimation, and biological evidence where justified.
- LC-MS, HRMS, MS/MS, and peptide mapping are the core tools for characterization.
- A new impurity is not automatically high-risk, and a low level is not automatically safe. Risk must be judged in context.
- On July 28, 2026, FDA published 17 revised draft product-specific guidances for certain generic peptides and withdrew its May 2021 guidance on highly purified synthetic peptides. Always check the guidance for your specific RLD.
- This article is an illustrative case study. It is not a report of an actual ResolveMass client engagement or experimental result.
1: What Is Immunogenicity Risk Assessment of Peptide Impurities?
It is a structured scientific evaluation of whether an impurity could contribute to an unwanted immune response, considering its identity, structure, amount, biological relevance, route of administration, and patient exposure.
Immunogenicity is the ability of a substance to provoke an immune response. For therapeutic peptides, this may mean anti-drug antibodies (ADAs), which can affect drug activity, pharmacokinetics, safety, or effectiveness.
Detecting an impurity does not mean it is immunogenic, and a low concentration does not by itself prove it is safe. The factors that matter are:
| Factor | Question to answer |
|---|---|
| Chemical identity | Is it a deletion, insertion, oxidized, deamidated, or other variant? |
| Structural differences | Does it change conformation, charge, hydrophobicity, or aggregation? |
| Exposure | What are its concentration, maximum daily dose, treatment duration, and route? |
| Biological plausibility | Is there evidence it could alter immune recognition? |
| Product context | Is it also present in the RLD, or does the generic introduce a new risk? |
Not every impurity needs immunogenicity testing. The goal is to find credible risks, judge the strength of the evidence, and decide what further work is scientifically justified.
2: Where Do Peptide Impurities Come From?
They come from the manufacturing process, from degradation, or from both. Synthetic peptides made by solid-phase peptide synthesis (SPPS) have a different impurity profile from products made in biological systems. Understanding peptide synthesis vs protein manufacturing helps explain why a generic synthetic peptide can contain impurities the RLD does not.
| Impurity type | Typical origin |
|---|---|
| Deletion sequences | Incomplete coupling during synthesis |
| Insertion sequences | Excess reagent or double coupling |
| Oxidized or deamidated forms | Synthesis, storage, or degradation |
| Stereochemical variants (epimers) | Racemization during coupling or cleavage |
| Aggregates | Handling, formulation, or storage |
Modified peptides add further complexity. For example, conjugated products need their own approach, as described in our guide to PEGylated peptide characterization.
3: Case Study: Investigating a Newly Detected Impurity in a Generic Peptide ANDA
This case is hypothetical. The impurity identity, results, and decisions are illustrative, not findings from an actual project.
Background: A manufacturer developing a generic synthetic peptide detects an unexpected peak in a routine HPLC chromatogram. The peak is not explained by the existing impurity profile.
The key question: Could this new impurity introduce a meaningful safety or immunogenicity concern compared with the reference product?
The impurity should not be classed as high-risk merely because it is new. The team first establishes its identity, judges the quality of the evidence, and then decides whether it could alter the product’s relevant biological properties.
4: How Should a New Peptide Impurity Be Characterized?
Use complementary analytical techniques together, because retention time alone cannot establish the identity of an unknown peptide impurity.
| Technique | Purpose |
|---|---|
| RP-HPLC / UPLC | Separate the impurity and assess relative abundance |
| LC-MS | Determine mass-to-charge information and molecular mass |
| HRMS | Provide accurate mass to support an elemental-composition hypothesis |
| LC-MS/MS | Generate fragment ions to locate sequence changes or modifications |
| Peptide mapping | Compare sequence-related characteristics and identify modified regions |
| NMR (when justified) | Add structural detail if enough material is available |
| MALDI-TOF MS | Offer a rapid, complementary molecular weight check (see MALDI-TOF mass spectrometry for peptide characterization) |
These methods give complementary evidence. A mass shift consistent with oxidation supports an oxidation hypothesis, but it may not pinpoint the modification site. Fragmentation data and orthogonal evidence are often needed.
The team should document the proposed identity, supporting evidence, remaining uncertainties, and the limits of each method. Reliable data also depends on a fit-for-purpose method, so see our guidance on peptide analytical method development and validation.
5: How Should the Impurity Be Compared With the Reference Listed Drug?
Compare representative generic and RLD batches using sensitive, specific methods to learn whether the impurity is unique to the generic, present at a different level, or also detectable in the RLD.
FDA’s guidance on synthetic peptides stresses comparing the types and amounts of impurities in a proposed generic with those in the RLD. New impurities need justification that addresses potential differences in safety, including immunogenicity.
A comparison plan may include:
- Analyzing representative generic and RLD batches with suitable chromatographic methods
- Comparing retention times, relative abundance, and MS profiles
- Confirming method sensitivity and specificity for the impurity
- Checking that sample preparation or storage did not create the impurity
- Reviewing batch-to-batch consistency and stability data
| Comparison question | Why it matters |
|---|---|
| Is it detectable in the RLD? | Shows whether it is truly new or just below detection |
| Is the level higher in the generic? | Identifies a difference that needs justification |
| Does it increase during storage? | May indicate a degradation product needing stability controls |
| Is it structurally different from the peptide? | Guides further characterization or biological evaluation |
Failing to detect an impurity in the RLD does not prove it is absent. The conclusion depends on method sensitivity, selectivity, sampling, and the batches examined. For submission planning, see our page on peptide characterization for ANDA submission.
6: How Can Immunogenicity Risk Be Assessed?
Use a weight-of-evidence approach that integrates structural characterization, exposure, product comparison, and appropriate biological evidence. The outcome should be a justified risk conclusion, not an assumption based on concentration alone.
The four-stage framework
| Stage | Focus |
|---|---|
| 1. Structural risk | Does the impurity change the sequence, modify an amino acid, affect conformation, or involve aggregation? |
| 2. Exposure risk | How much impurity per dose, and what cumulative exposure under the proposed regimen? |
| 3. Biological plausibility | Is in silico, in vitro, or other nonclinical evidence needed? |
| 4. Integrated conclusion | Combine all evidence, state uncertainties, and specify risk controls |
Which biological studies may be appropriate?
Study selection depends on the peptide, the impurity, product-specific regulatory expectations, and the uncertainty left after analytical work.
- In silico assessment: Evaluates sequence or structural features computationally. Predictions do not establish actual immunogenicity.
- In vitro innate immune assays: Investigate whether the impurity-containing sample activates relevant immune pathways, when a justified assay exists.
- Antigen-specific T-cell assays: Considered when the impurity’s characteristics and the regulatory context warrant them.
- Other targeted studies: Used only to address a defined uncertainty, with proper controls.
Assay suitability, validation, sample representativeness, and model limitations all matter. A negative result in one assay does not prove an impurity cannot trigger an immune response in humans. ADA testing guidance written for therapeutic proteins may apply to some peptides case by case, but it should not be applied automatically to every synthetic peptide impurity.
7: How Should Impurity Exposure Be Estimated?
Multiply the measured impurity level by the dose to estimate how much a patient could receive, then treat that number as one input to the risk assessment rather than a safety threshold.
Document the following:
- Measured impurity concentration in the drug substance or product
- Maximum intended daily dose
- Route and frequency of administration
- Expected treatment duration
- Uncertainty in the analytical measurement
Worked example (hypothetical): If a product contains 0.20% of an impurity relative to peptide content and the dose is 10 mg, the impurity amount is 0.02 mg, or 20 micrograms, per dose.
This assumes the percentage is a valid mass-based ratio. HPLC area percent is not automatically equal to mass percent, because different compounds have different detector responses. Use a justified quantitative method, ideally supported by a reference standard.
8: What Regulatory Considerations Apply to a Generic Peptide ANDA?
A generic peptide ANDA must meet the product-specific expectations for its reference product and justify any impurity differences that could affect quality, safety, or effectiveness.
On July 28, 2026, FDA published 17 revised draft product-specific guidances for certain generic peptide products. The drafts address impurity thresholds, innate immune response testing, higher-order structure, and biological activity. FDA also withdrew its May 2021 guidance on certain highly purified synthetic peptides because it no longer reflected current scientific thinking. The revised recommendations are product-specific drafts, not final guidance. Teams should confirm current wording on FDA’s website before relying on any of this.
| Consideration | Recommended action |
|---|---|
| Product-specific guidance | Identify current FDA recommendations for your peptide and RLD |
| Impurity identification | Establish identity with suitable analytical evidence |
| Comparative profile | Compare generic and RLD with appropriate methods and samples |
| Immunogenicity concerns | Address plausible risks with justified evidence |
| Impurity controls | Set specifications, monitoring, and manufacturing controls |
| Documentation | Present methods, results, assumptions, and uncertainties traceably |
No single impurity threshold or assay applies to every peptide. Where uncertainty remains, early regulatory interaction can clarify what evidence is expected.
9: What Might the Outcome of the Case Study Look Like?
A documented, evidence-based risk conclusion with clear next steps. Because this case is hypothetical, no actual low-risk or high-risk result is claimed. Possible outcomes include:
| Outcome | Meaning |
|---|---|
| Identity established, concern addressed | Impurity characterized, comparison satisfactory, controls supported |
| Additional evidence required | Identity or biological relevance still uncertain |
| Manufacturing improvement required | Impurity tied to a controllable synthesis, purification, formulation, or storage issue |
| Specification or process controls revised | Existing control strategy cannot manage the impurity consistently |
A final report should summarize identity, methods, comparative findings, estimated exposure, biological evidence, remaining uncertainties, and the proposed control strategy. It should clearly separate demonstrated findings from interpretations and hypotheses.
Common Pitfalls to Avoid
- Relying on a single chromatographic method that can hide co-eluting species
- Comparing too few RLD batches
- Treating in silico results as definitive
- Equating HPLC area percent with mass percent
- Applying an outdated or non-product-specific guidance
- Presenting inconsistent data across submission modules
How Can ResolveMass Support Peptide Impurity Characterization?
ResolveMass Laboratories Inc. provides analytical support, including chromatographic and mass-spectrometric characterization, that helps teams investigate unexpected impurities and generate data for quality assessments.
Depending on the project, this may include:
- HPLC-based impurity profiling and method development
- LC-MS and complementary mass-spectrometric characterization
- Investigation of peptide modifications and degradation products
- Method optimization and validation support
- Comparative studies and impurity-profile interpretation
- Technical documentation to support development decisions
The scope should be set after reviewing the peptide, available reference materials, objectives, and regulatory expectations. Immunogenicity conclusions need appropriate supporting evidence and should not be inferred from analytical characterization alone.
Conclusion:
Immunogenicity Risk Assessment of Peptide Impurities is an evidence-based part of evaluating unexpected impurities in generic peptide development. A reliable assessment starts with structural characterization, compares the product with the RLD, estimates patient exposure, and decides whether biological studies or manufacturing controls are justified.
FDA’s July 2026 revised draft product-specific guidances reinforce the need to consider the specific peptide and its regulatory expectations, so teams should verify current guidance before finalizing a strategy. Fit-for-purpose methods, a justified risk evaluation, and transparent documentation help teams make better-informed decisions about impurity control and ANDA readiness.
Frequently Asked Questions:
Factors that may increase immunogenicity concerns include changes in amino acid sequence, chemical modifications, aggregation, altered peptide structure, and impurities that may activate immune pathways. The actual risk depends on the specific impurity, exposure, product characteristics, and supporting scientific evidence.
Peptide impurity profiling identifies and quantifies impurities present in a drug substance or product. Immunogenicity assessment evaluates whether those impurities could contribute to an unwanted immune response. Impurity profiling provides essential analytical evidence, but it cannot independently establish immunogenicity.
Comparing the proposed generic product with the reference listed drug helps determine whether the products have comparable impurity profiles or contain meaningful differences. A newly detected impurity may require additional characterization, exposure assessment, or regulatory justification, depending on its properties and the applicable guidance.
Oxidation and deamidation can alter a peptide’s chemical structure and may influence its stability, conformation, biological activity, or interactions with the immune system. However, these modifications do not automatically make a peptide immunogenic. Their significance must be evaluated using product-specific analytical and biological evidence.
Forced degradation studies investigate how peptides respond to conditions such as oxidation, heat, light, and pH changes. They help identify degradation pathways, support stability-indicating analytical method development, and distinguish degradation-related impurities from other process-related impurities. Study conditions should be selected according to the peptide’s properties and the investigation objectives.
No. In silico tools can identify potential sequence-related concerns and help prioritize further investigations, but their predictions have limitations. Depending on the impurity and the available evidence, complementary analytical or biological studies may be necessary.
Reference
- De Groot AS, Roberts BJ, Mattei A, Lelias S, Boyle C, Martin WD. Immunogenicity risk assessment of synthetic peptide drugs and their impurities. Drug Discovery Today. 2023 Oct 1;28(10):103714.https://www.sciencedirect.com/science/article/pii/S1359644623002301
- Mattei AE, Roberts BJ, Lelias S, Miah S, Howard KE, Weaver JL, Verthelyi D, Pang ES, Edwards K, De Groot AS. Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products. Frontiers in Immunology. 2025 Dec 8;16:1730346.https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1730346/full
- Roberts BJ, Mattei AE, Howard KE, Weaver JL, Liu H, Lelias S, Martin WD, Verthelyi D, Pang E, Edwards KJ, De Groot AS. Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods. Frontiers in Pharmacology. 2024 Aug 9;15:1363139.https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1363139/full
- Puig M, Shubow S. Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors. Frontiers in immunology. 2025 Jun 18;16:1608401.https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1608401/full
About the Author
